scholarly journals Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 9 (8) ◽  
pp. 8120-8132
Author(s):  
Duanrui Liu ◽  
Xiaoli Ma ◽  
Dongjie Xiao ◽  
Yanfei Jia ◽  
Yunshan Wang
Andrologia ◽  
2020 ◽  
Vol 52 (11) ◽  
Author(s):  
Hanchao Liu ◽  
Mingxiao Zhang ◽  
Mingchuan Huang ◽  
Hongcai Cai ◽  
Yadong Zhang ◽  
...  

2019 ◽  
Vol 17 ◽  
pp. 205873921983109
Author(s):  
Zhigui Li ◽  
Zhaofen Xu ◽  
Yuqian Huang ◽  
Yong Wang ◽  
Hare Ram Karn ◽  
...  

The systemic inflammation plays a crucial role in carcinogenesis and cancer progression. Pretreatment lymphocyte-to-monocyte ratio (LMR) has been suggested to be associated with clinical outcomes in various malignancies. To evaluate the prognostic significance of pretreatment LMR on gastric cancer, we conducted a comprehensive literature search in PubMed, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov (Prospero Registration No. CRD42018087263). This meta-analysis included all studies evaluating the prognostic significance of pretreatment LMR on gastric cancer. The main outcome measures included overall survival (OS), progression-free survival (PFS), and the relationship between LMR and clinicopathological features. In total, 11 studies (12 cohorts) enrolling 14,262 patients with gastric cancer were included. The pooled estimates showed that elevated pretreatment LMR was significantly associated with better OS (hazard ratio (HR): 0.71, 95% confidence interval (CI): 0.58–0.83) and better PFS (HR: 0.71, 95% CI: 0.44–0.99). The elevated LMR was also significantly associated with young patients, female, low level of carcinoembryonic antigen (CEA), low level of carbohydrate antigen 19-9 (CA19-9), stage I–II, small tumor size, absence of lymph node metastasis, absence of vascular invasion, and absence of perineural invasion. In conclusion, the elevated pretreatment LMR predicted the better clinical outcomes in patients with gastric cancer.


In Vivo ◽  
2020 ◽  
Vol 34 (6) ◽  
pp. 3115-3125
Author(s):  
CHIKARA KUNISAKI ◽  
SHO SATO ◽  
NOBUHIRO TSUCHIYA ◽  
JUN WATANABE ◽  
TSUTOMU SATO ◽  
...  

2019 ◽  
Vol 5 (3) ◽  
pp. 178-188
Author(s):  
Hao Nie ◽  
Yang Hu ◽  
Zhouping Tang

Background: Randomized controlled trials (RCTs) that directly compare the efficacy and safety of percutaneous patent foramen ovale (PFO) closure devices have not been conducted. Thus, we performed a network meta-analysis to identify the efficacy and safety of occluder devices. Methods: From 1st January, 2000 to 1st May, 2018, we searched Embase, PubMed, and Cochrane Library for RCTs about percutaneous closure devices (such as STARFlex, GORE, and Amplatzer) and medical therapy for cryptogenic cerebral ischemic patients with PFO. The occurrence rate of recurrent stroke, atrial fibrillation (AF), major vascular complication (MVC), headache, transient ischemic attack, and bleeding were compared with the frequentist and Bayesian methods using R statistics. Results: We included 3747 patients from six RCTs. The GORE and Amplatzer occluders were found to be significantly associated with a decreased risk of recurrent stroke [relative risk (RR): 0.37 and 0.49; 95% confidence interval (CI): 0.17–0.81, 0.29–0.83, respectively]. Moreover, STARFlex was correlated to an increased risk of postoperative AF and MVCs (RR: 11.66 and 7.63; 95% CI: 4.87–21.91, 2.34–24.88). Conclusions: Among the three devices, the GORE and Amplatzer occluders are found to be the most effective in preventing secondary stroke in patients with PFO. Meanwhile, STARFlex is the least recommended device because it cannot decrease the risk of recurrent stroke and is the most likely to cause adverse events.


Oncotarget ◽  
2017 ◽  
Vol 8 (40) ◽  
pp. 68873-68889 ◽  
Author(s):  
Dan Zhang ◽  
Jiewen Zheng ◽  
Mengwei Ni ◽  
Jiarui Wu ◽  
Kuaihuan Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document